What happened
Samsung Biologics disclosed a subsidiary's acquisition of PolyPeptide Group AG, worth $2.0B (₩2.7T).
For context, this deal is worth about 24.5% of the company's consolidated total assets.
| Target | PolyPeptide Group AG |
|---|---|
| Deal value | $2.0B (₩2.7T) |
| vs. company assets | 24.5% |
| Filed | 2026-08-31, 타법인주식및출자증권취득결정(종속회사의주요경영사항) |
| Source | DART rcept 20260831800556 → open original filing |
Source: DART. Information only, not investment advice.